Morningside Venture Investments Ltd - Feb 22, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
10%+ Owner
Signature
/s/ Frances Anne Elizabeth Richard, Director
Stock symbol
AMLX
Transactions as of
Feb 22, 2023
Transactions value $
-$3,578,103
Form type
4
Date filed
2/24/2023, 03:13 PM
Previous filing
Feb 7, 2023
Next filing
Feb 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale -$1.43M -39.9K -0.52% $35.91 7.64M Feb 22, 2023 Direct F1, F5
transaction AMLX Common Stock Sale -$366K -10.1K -0.13% $36.34 7.63M Feb 22, 2023 Direct F2, F5
transaction AMLX Common Stock Sale -$1.74M -48.9K -0.64% $35.55 7.58M Feb 23, 2023 Direct F3, F5
transaction AMLX Common Stock Sale -$40.3K -1.11K -0.01% $36.24 7.58M Feb 23, 2023 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.20 to $36.20, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.21 to $36.52, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.14 to $36.14, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.15 to $36.36, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F5 Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL.